Qianqian Song | Computational Biology | Best Researcher Award

Published on by Awards and Recognitions

Best Researcher Award

Qianqian Song
Purdue University

Qianqian Song
Affiliation Purdue University
Country United States
Scopus ID 56768861500
Documents 100
Citations 4,360
h-index 34
Subject Area Computational Biology
Event Research Awards and Recognitions
ORCID 0000-0002-4455-5302

Qianqian Song is a researcher affiliated with Purdue University in the United States whose documented scholarly profile is associated with computational biology. The supplied research metrics indicate 100 documents, 4,360 citations, and an h-index of 34. These indicators provide a bibliometric overview of publication activity and citation impact and are presented as profile-level measures rather than as a qualitative assessment of individual research contributions.[1]

Abstract

Qianqian Song, affiliated with Purdue University, United States, is presented in the context of the Best Researcher Award under Research Awards and Recognitions. The supplied profile identifies computational biology as the principal subject area and reports 100 documents, 4,360 citations, and an h-index of 34. Together, these bibliometric indicators describe the documented scale and citation visibility of the research record. The profile can be considered alongside publication records, institutional affiliation, and persistent researcher identifiers when reviewing the academic record.[1]

Keywords

  • Qianqian Song
  • Computational Biology
  • Researcher Profile
  • Bibliometrics
  • Research Impact
  • Best Researcher Award

Introduction

Computational biology combines computational methods with biological research to support the analysis and interpretation of complex biological data. Researchers working in this area may contribute through computational modelling, data analysis, biological informatics, and interdisciplinary approaches. Within this context, Song’s supplied profile is associated with Purdue University and the subject area of computational biology.

Research Profile

The supplied bibliometric profile records 100 documents and 4,360 citations, with an h-index of 34. The Scopus author identifier is 56768861500, while the ORCID identifier is 0000-0002-4455-5302. These persistent identifiers can assist with distinguishing an author’s scholarly record from other researchers with similar names.[1]

Research Contributions

The available information identifies computational biology as Song’s subject area but does not provide a sufficiently detailed publication-by-publication account to characterize specific discoveries or methodological advances. Accordingly, the research contribution described here is limited to the documented field affiliation and bibliometric record. A more detailed assessment would require examination of individual publications, research topics, methods, and cited scholarly evidence.

Publications

The supplied profile reports 100 documents. Individual publication titles, journals, publication years, and DOI information were not provided in the input data. For that reason, no specific publication or DOI is attributed to Song on this page without additional bibliographic verification. The Scopus author profile and Google Scholar profile provide appropriate starting points for reviewing the publication record.[1]

Research Impact

Citation counts and h-index values are commonly used as bibliometric indicators of scholarly visibility. The supplied figures of 4,360 citations and an h-index of 34 indicate the scale of the documented citation record at the time represented by the source information. Such indicators should be interpreted in relation to field, career stage, publication practices, and database coverage rather than as standalone measures of research quality.[1]

Award Suitability

For the Best Researcher Award profile presented by Research Awards and Recognitions, the supplied record includes an identifiable institutional affiliation, a defined subject area, persistent researcher identifiers, and substantial bibliometric information. These details provide documented criteria that can be considered as part of an award profile. Final recognition decisions remain subject to the applicable award organization’s review and evaluation procedures.

Conclusion

Qianqian Song’s supplied academic profile connects Purdue University with computational biology and records 100 documents, 4,360 citations, and an h-index of 34. The Scopus and ORCID identifiers provide additional mechanisms for identifying the research record. While these metrics summarize publication and citation activity, a comprehensive scholarly evaluation should also consider the content, originality, methodological quality, and broader significance of individual research outputs.

References

  1. Elsevier. (n.d.). Scopus author details: Qianqian Song, Author ID 56768861500. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=56768861500
  2. ORCID. (n.d.). Qianqian Song — ORCID record.
    https://orcid.org/0000-0002-4455-5302
  3. Google Scholar. (n.d.). Qianqian Song — Google Scholar profile.
    https://scholar.google.com/citations?user=wIYviKIAAAAJ&hl=en

 

Sara Garcia-Rates | Neuroscience | Research Excellence Award

Published on by Awards and Recognitions

Research Excellence Award

Sara Garcia-Rates
Neuro Bio Ltd, United Kingdom
Sara Garcia-Rates
Affiliation Neuro Bio Ltd
Country United Kingdom
Scopus ID 23388862700
Documents 26
Citations 336
h-index 11
Subject Area Neuroscience
Event Research Awards and Recognitions
ORCID 0000-0002-1848-4811

Sara Garcia-Rates is a neuroscience researcher and biotechnology executive associated with Neuro Bio Ltd. With more than two decades of experience, her work focuses on neuroscience, neurodegenerative diseases, translational medicine, and biotechnology innovation. She has contributed to Alzheimer’s disease research through leadership in preclinical drug development, assay validation, intellectual property strategy, and scientific collaboration. Her academic background in pharmacology and biomedicine supports her role in advancing therapeutic development and translational research. Garcia-Rates combines scientific leadership with commercialization strategy, contributing to biomedical innovation and the development of novel approaches for neurodegenerative disease treatment.[1]

Abstract

Sara Garcia-Rates is a multidisciplinary neuroscience researcher specializing in neurodegenerative disease therapeutics, Alzheimer’s disease drug discovery, and translational biotechnology. Her work includes developing preclinical research strategies, expanding biotechnology patent portfolios, and advancing therapeutic candidates through international scientific collaborations. She has also contributed to neuropharmacology research focused on nicotinic receptor biology, neurotoxicity mechanisms, and receptor-mediated signaling pathways, establishing a strong profile in neuroscience innovation and therapeutic development.[2]

Keywords

Neuroscience, Alzheimer’s disease, neuropharmacology, biotechnology, translational medicine, preclinical development, nicotinic receptors, neurodegeneration, therapeutics, pharmacology, biotechnology leadership, drug discovery, intellectual property, neuroscience innovation.

Introduction

Sara Garcia-Rates has built an interdisciplinary research profile combining neuroscience, biotechnology, and translational medicine. Her work focuses on neurodegenerative diseases, neuronal signaling, receptor modulation, and therapeutic development, alongside contributions to biotechnology management, patent development, research funding, and scientific collaborations.[3]

Sara Garcia-Rates received advanced training in biology, pharmacology, and biomedicine at the University of Barcelona and completed postdoctoral research at the University of Oxford Department of Pharmacology. Her career combines academic neuroscience research with biotechnology leadership, focusing on translational biomedical science and therapeutic innovation.[2]

Research Profile

Sara Garcia-Rates serves as Chief Scientific Officer at Neuro Bio Ltd, where she has contributed since 2013. Her work includes leading preclinical neuroscience research, therapeutic development, experimental assay design, and intellectual property strategy. [1]

Her leadership includes overseeing scientific projects, managing multidisciplinary teams, and coordinating collaborative partnerships. Under her direction, the organization expanded its patent portfolio from two patents to twenty-two patent families related to neurodegeneration, oncology, anti-aging research, and therapeutic technologies.[4]

Sara Garcia-Rates has also contributed to funding acquisition strategies, scientific advisory board activities, and partnerships with universities, contract research organizations, and industrial collaborators. These activities illustrate the integration of scientific research with translational commercialization and innovation management within the biotechnology sector.[5]

Research Contributions

Garcia-Rates has contributed to neuroscience research on nicotinic receptors, neurotoxicity, intracellular signaling, and the effects of methamphetamine and MDMA exposure. Her studies focus on receptor-mediated pathways, oxidative stress, and neurochemical regulation in experimental systems.[2]

Her translational research includes developing therapeutic candidates for Alzheimer’s disease at Neuro Bio Ltd. She contributed to the evaluation and optimization of nearly two hundred compounds, supporting the development of preclinical therapies and patent-protected technologies for neurodegenerative disorders.[4]

Additional contributions include establishment of research partnerships across the United Kingdom and international biotechnology networks. Her work in collaborative development has supported external scientific collaborations, intellectual property growth, and strategic development of biotechnology assets involving therapeutic and diagnostic innovation.[5]

  • Leadership of Alzheimer’s disease therapeutic development programs.
  • Expansion of biotechnology patent portfolios and translational research assets.
  • Research on nicotinic receptor pharmacology and neurotoxicity.
  • Coordination of interdisciplinary scientific collaborations and advisory activities.
  • Management of preclinical neuroscience development programs.

Publications

Sara Garcia-Rates has published research in neuropharmacology, receptor biology, and neuroscience, focusing on neurotoxicity, nicotinic receptor regulation, intracellular signaling, and neurochemical mechanisms. Her work contributes to the understanding of receptor-mediated neurological disorders and includes both scientific journal articles and book chapters on methamphetamine- and MDMA-related neurotoxicity.[2]

  1. Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology, 2007.
  2. Chipana C, García-Ratés S, Camarasa J, Pubill D, Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and MDMA. Neurochemistry International, 2008.
  3. Garcia-Ratés S, Camarasa J, Sánchez-García AI, Gandía L, Escubedo E, Pubill D. Effects of MDMA on nicotinic receptors and intracellular calcium increase. Toxicology and Applied Pharmacology, 2010.
  4. Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals, 2011.

Research Impact

The research activities of Sara Garcia-Rates demonstrate impact across both academic neuroscience and biotechnology innovation. Her publication metrics include twenty-six indexed documents, more than three hundred citations, and an h-index of eleven, reflecting measurable scholarly engagement within the neuroscience research community.[1]

Garcia-Rates has contributed to biotechnology development through preclinical therapeutic research, patent expansion, and translational neuroscience projects focused on neurodegenerative diseases. She has also supported commercialization efforts, investment acquisition, and research funding to advance biotechnology innovation and organizational growth.[4]

Her scientific leadership has also included mentoring activities, partnership development with academic institutions, and participation in scientific advisory initiatives. These contributions indicate broader influence beyond publication metrics alone, extending into organizational development and interdisciplinary scientific collaboration.[5]

Award Suitability

Sara Garcia-Rates combines expertise in neuroscience research, translational biomedical science, and biotechnology leadership. Her work in therapeutic development, scientific publications, intellectual property expansion, and collaborative research reflects sustained contributions to neuroscience and biotechnology innovation.[3]

Her ability to lead multidisciplinary scientific projects and contribute to translational therapeutic development highlights her role in modern biomedical research. Her work in therapeutic innovation, patent expansion, and scientific collaboration demonstrates continued engagement in neuroscience research and biotechnology advancement.[4]

Conclusion

Sara Garcia-Rates has built a multidisciplinary career in neuroscience research, biotechnology leadership, and therapeutic development. Through her work at Neuro Bio Ltd and her scientific publications, she has contributed to neuropharmacology research, Alzheimer’s disease therapeutics, and biotechnology innovation.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Sara Garcia-Rates, Author ID 23388862700. Scopus. https://www.scopus.com/authid/detail.uri?authorId=23388862700
  2. Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. (2007). Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2007.05.019
  3. Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. (2011). Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals. https://doi.org/10.3390/ph4060822
  4. Neuro Bio Ltd. (2025). Research development activities, patent portfolio expansion, and preclinical neuroscience initiatives. 
  5. Awards and Recognitions. (n.d.). Research Awards and Recognitions official website. https://awardsandrecognitions.com/